SEATTLE--(BUSINESS WIRE)--June 26, 2006--Northstar Neuroscience, Inc. (NASDAQ: NSTR - News), a developer of medical devices for the treatment of neurological diseases and disorders, today announced the completion of patient enrollment and randomization in its feasibility study of cortical stimulation to treat stroke-related Broca’s aphasia (or non-fluent aphasia). Called CHESTNUT, the study was designed to assess the safety and effectiveness of an investigational cortical stimulation system when used during speech-language rehabilitation. Approximately one million individuals in the United States suffer from aphasia, an impairment in speech or language. Currently, there are no proven treatments for aphasia beyond rehabilitation.
